The U.S FDA has approved Zogenix’s drug to treat seizures associated with a rare form of childhood epilepsy known as Dravet syndrome. The drug, branded as Fintepla, uses a low-dose liquid solution of fenfluramine, which was used in an obesity drug combination that was later withdrawn from the market due to evidence of heart valve damage. The approval contains a boxed warning, the FDA’s harshest, flagging concerns about valvular heart disease and pulmonary arterial hypertension, and is available only through a restricted drug distribution program. Learn More